All In Biotech

Free tool

FAERS Monitor: Ilumya

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761067 or its brand name (Ilumya, Tildrakizumab-Asmn). Reports on generic versions are filed under their own applications.

Reports

2,410

Serious

540

22% of reports

Hospitalization

94

Death reported

174

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue489
  • drug ineffective313
  • intentional dose omission215
  • death167
  • condition aggravated121
  • psoriasis109
  • off label use96
  • self-medication92
  • pruritus89
  • inappropriate schedule of product administration86
  • therapy cessation85
  • product storage error84
  • rash81
  • diarrhoea47
  • therapy interrupted43

Reports by year received

View as table
YearReports
20181
201983
2020127
2021168
2022217
2023154
2024339
2025591
2026730

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,749 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
self-medicationSignal92199.8163.117,602
intentional dose omissionSignal21566.358.313,679
product dose omission issueSignal48914.513.46,227
therapy cessationSignal8514.511.71,054
product storage errorSignal848.46.8540
psoriasisSignal1097.36.1588
therapy interruptedSignal435.33.9144
inappropriate schedule of product administrationSignal864.23.4205
condition aggravatedSignal1213.52.9214
drug ineffectiveSignal3132.11.9184
pruritusSignal892.01.646
death1671.71.549
rash811.61.319
off label use961.00.80
diarrhoea470.60.510

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.